Mathematically ranked by Value, Quality, and User Experience
This re-verification produced our biggest ranking shakeup ever, driven by a wave of FDA enforcement that hit the compounded GLP-1 industry through 2026. Five of the nine providers we evaluated now carry FDA warning letters. Our previous #1, MEDVi, received a warning letter in February 2026 and fell to last place. Last year's #6, Outlive Biology, exited the category entirely (it rebranded as OneTwenty, a longevity membership). Four providers joined the evaluation pool: Oak, Elevate, PeterMD, and Sprout Health. And brand-name manufacturers slashed their direct self-pay prices, which raised the bar every compounded program must clear.
Best for: Users who want the lowest verified flat price from a large, established platform — and who read our "what to watch" notes first.
Why it won: #1 in Value with $99/mo semaglutide and $129/mo tirzepatide at every dose — verified on their live site during this review — plus #2 in UX with fast approvals and free expedited shipping.
Key strength: A lifetime price lock with no membership fee, at roughly a third of the brand-name self-pay price.
Visit Eden →Best for: Users who care most about knowing exactly where their medication comes from.
Why it won: #1 in Quality — the only contender that names its compounding pharmacies, offers certificates of analysis on request, and has no FDA warning letter.
Key strength: The cheapest injectable pricing of any top-3 finisher, if you accept a commitment plan.
Visit Shed →Our referral link takes 40% off your first order
Best for: Users who want a clean regulatory record and unusually thorough medical screening, and accept a newer platform with a shorter track record.
Why it won: #2 in Quality — zero FDA actions across all three 2025–2026 enforcement waves, and intake screening (family thyroid-cancer history, full-body photo) more rigorous than most async competitors.
Key strength: Flat pricing across all doses with same-day approval in most states, in English or Spanish.
Visit Oak →💰 Hesitating because of cost? Several verified discounts are live right now — a 40% first-order referral, a standing $200-off code, $99/month flat pricing. See the live deals & Black Friday page →
Our AI Researcher gathers comprehensive data on each GLP-1 provider, including pricing structures, regulatory compliance, customer reviews, medical protocols, and service offerings. For this October 2026 re-verification that meant checking each provider's live checkout pricing, FDA warning-letter databases across all three 2025–2026 enforcement waves, Trustpilot and BBB complaint patterns, and pharmacy sourcing disclosures. This raw data forms the foundation for independent analysis by three specialized analyzers.
Evaluates medical oversight, physician credentials, screening protocols, safety measures, regulatory compliance, and pharmacy sourcing transparency. Prioritizes patient safety above all — and in 2026, that means FDA warning letters weigh heavily.
Assesses total cost of ownership including monthly fees, hidden charges, cancellation policies, and medication pricing — now benchmarked against brand-name direct-to-consumer prices, which fell sharply in 2026.
Examines user experience from sign-up to ongoing care: app quality, communication ease, prescription fulfillment speed, cancellation friction, and customer support responsiveness.
The Final Arbiter combines scores from all three analyzers using a mathematical point system: #1 earns 10 points, #2 earns 9 points, down to #10 earning 1 point. This ensures rankings are determined by data—not affiliate bias or human override. In case of ties, Quality score serves as the primary tiebreaker to prioritize patient trust.
| Provider | Value Rank (Pts) | Quality Rank (Pts) | UX Rank (Pts) | Total | Final Rank |
|---|---|---|---|---|---|
| Eden | #1 (10 pts) | #4 (7 pts) | #2 (9 pts) | 26 pts | 🥇 #1 |
| Shed (ShedRx) | #3 (8 pts) | #1 (10 pts) | #5 (6 pts) | 24 pts | 🥈 #2 |
| Oak | #6 (5 pts) | #2 (9 pts) | #3 (8 pts) | 22 pts | 🥉 #3 |
| Remedy Meds | #9 (2 pts) | #3 (8 pts) | #1 (10 pts) | 20 pts | #4 |
| Sprout Health | #2 (9 pts) | #7 (4 pts) | #7 (4 pts) | 17 pts | #5 |
| Elevate | #7 (4 pts) | #6 (5 pts) | #4 (7 pts) | 16 pts | #6 |
| PeterMD | #5 (6 pts) | #5 (6 pts) | #8 (3 pts) | 15 pts | #7 |
| OrderlyMeds | #4 (7 pts) | #9 (2 pts) | #6 (5 pts) | 14 pts | #8 |
| MEDVi | #8 (3 pts) | #8 (3 pts) | #9 (2 pts) | 8 pts | #9 |
Note: Outlive Biology, ranked #6 in our previous verification, was removed from scoring — it rebranded as OneTwenty, a beta-stage longevity membership, and no longer operates as a GLP-1 weight-loss provider. Details in the FAQ below.
Traditional review sites rely on a single reviewer who may be influenced by affiliate commissions, personal preferences, or incomplete research. Our five-role system creates mathematical objectivity through independent analysis. Each analyzer evaluates providers without knowledge of how others scored them, and the Final Arbiter combines these scores using a transparent point system. This eliminates the possibility of bias influencing rankings—the math determines the winners, not human judgment. The proof is on this page: our previous #1 held the top spot for a year, and when the 2026 data turned against it, it fell to last. The math doesn't play favorites.
The lowest verified flat price in the category, from a platform operating at scale
Eden takes the top spot on the strength of a price claim we could actually verify: during this review we confirmed $99/month compounded semaglutide and $129/month compounded tirzepatide on Eden's live site — flat at every dose, with a "lifetime price guarantee," no membership fee, and cancel-anytime terms. In a year when brand-name Wegovy costs $349/month direct from the manufacturer, that is the widest genuine price gap left in this category.
The platform claims 200,000+ members, holds a 4.4+ Trustpilot rating across thousands of reviews, turns around prescriber decisions in 24–48 hours, and ships expedited at no charge. It also names its four PCAB-accredited compounding pharmacies — transparency several higher-priced rivals don't offer. Treatment is dispensed through 503A pharmacies with support available around the clock, and HSA/FSA payment is accepted.
⚠️ What to watch: Eden received an FDA warning letter on June 8, 2026, for labeling that displayed "Eden" as the manufacturer and for a false "FDA-licensed" facility claim — a marketing violation, not a drug-safety finding, but you should know it exists. Eden also carries an F rating at the BBB with a pattern of slow complaint responses (mostly cancellation and refund friction on prepaid multi-month plans), and it restructured its pricing more than once in 2026.
Our advice: stick to the monthly plan rather than prepaying quarters, screenshot the price you sign up at, and confirm the checkout total matches the advertised $99/$129 before paying.
Review pattern across ~4,000 Trustpilot reviews: consistent praise for approval speed, responsive 24/7 messaging, and prices that undercut every competitor — with the recurring complaint cluster centered on refunds and cancellation when users prepaid quarterly instead of going month-to-month.
— Aggregated from Trustpilot & BBB complaint data, October 2026Users whose top priority is paying the least per month for a GLP-1 program from an established, high-volume platform — and who take the five minutes to read the billing terms we flagged above. On a monthly plan with eyes open, Eden is the strongest overall offer in the category right now.
✓ $99/mo semaglutide • ✓ Lifetime price lock • ✓ #1 Value rating
The only top contender that tells you exactly which pharmacy makes your medication
In a year defined by FDA enforcement, Shed is the only provider in our top four with no FDA warning letter — and the only contender that publicly names its compounding pharmacies (Strive, Promise, and Foothills, all 503A facilities) and offers certificates of analysis on request. When you can't rely on FDA approval, knowing exactly who made your medication is the single best substitute, and Shed is alone in offering it.
It's also the value runner-up: semaglutide injections run $199/month with no commitment, falling to $159/month on a 12-month plan, and tirzepatide runs $299 down to $239. Shed still offers the category's widest format range — injections, drops, and lozenges — after rebranding from ShedRx and cutting prices in late 2025. Brand-name medication is available through manufacturer-direct channels as well.
⚠️ What to watch: Shed's weak spot is logistics and billing discipline, not medicine. Its BBB file shows roughly 150 complaints in the past year — mostly billing cycles that continue while shipments lag, and cancellation friction against a two-month minimum commitment with a 72-hour notice window. The headline $159/$239 prices require a 12-month commitment; the real month-to-month prices are $199/$299. A law firm is also pursuing individual arbitration claims over older "same active ingredient" advertising. Go month-to-month first, and don't prepay until the first two cycles arrive on time.
Review pattern: the current Trustpilot profile runs 4.6 stars with praise for pricing and the coaching add-ons, while the complaint cluster — on BBB and the older domain's reviews — centers on being billed on schedule while shipments ran late, and on the two-month minimum catching people off guard.
— Aggregated from Trustpilot & BBB complaint data, October 2026Users who care most about medication provenance — named pharmacies, testing documentation, a clean regulatory record — and budget hunters willing to trade some shipping patience for the lowest injectable prices among the leaders. Needle-averse users also land here: nobody else in the top 3 offers drops and lozenges.
✓ Named pharmacies & COAs • ✓ No FDA warning letter • ✓ From $159/mo
Our referral link takes 40% off your first order — rankings are scored on list prices, discount or not.
Zero FDA actions, unusually rigorous screening, flat pricing — and a short track record
Oak (Oak Loves You, by Oak Longevity) is new to our rankings this year and enters at #3 on the strength of what it doesn't have: no FDA warning letter in any of the three 2025–2026 enforcement waves, no lawsuits we could find, and no complaint-pattern alerts. In this year's field, a clean sheet is a genuine differentiator.
Its intake screening also goes beyond the async-telehealth norm — it screens for personal and family history of medullary thyroid cancer and MEN-2 and requires a full-body photo before a prescriber decision, which most one-questionnaire competitors skip. Approval is typically same-day, pricing is flat across doses ($235/month semaglutide and $285/month tirzepatide on true month-to-month plans), health coaching and shipping are free, and it's the only ranked provider operating fully in both English and Spanish.
⚠️ What to watch: Oak is young (operating since late 2023) and thin on public proof — around 54 Trustpilot reviews, an unrated BBB file, undisclosed compounding pharmacy partners, and no publicly named leadership team. The advertised "from $119/month" pricing requires a long commitment; the real month-to-month prices are the $235/$285 we quote above. There are no refunds once medication ships, and the terms include a binding arbitration clause. Our analyzers' biggest internal debate this cycle was how to weigh Oak's clean record against that short paper trail — it earns the bronze, with that asterisk attached.
Review pattern: a 4.4-star Trustpilot average with praise for same-day approvals and the included coaching — but from a small review base, with the few complaints centering on delivery-address failures and a support desk that feels like a very small team.
— Aggregated from Trustpilot & BBB data, October 2026Users who rank regulatory cleanliness and screening rigor above a long public track record, Spanish speakers who want a fully bilingual program, and anyone who wants flat dose pricing with same-day approval. Pay monthly, skip the commitment plans, and the risk profile stays reasonable.
✓ No FDA actions • ✓ Rigorous screening • ✓ English & Spanish
Six more providers were fully evaluated this cycle. Here's where they landed and why.
The best care model in the category — a required video consultation before prescribing — and the best patient portal. But at $299/month semaglutide and $399/month tirzepatide, it now costs brand-name money for a compounded product, and it carries an unresolved September 2025 FDA warning letter plus an F at the BBB for post-cancellation billing complaints. remedymeds.com
The cheapest tirzepatide in this field — $199/month with no commitment, $149/month prepaid annually — with flat any-dose pricing. But Sprout received a September 2025 FDA warning letter for misbranding (since corrected on-site), holds a BBB F with 32 unanswered complaints, doesn't disclose its pharmacy partners, and its leadership is anonymous. The classic value-versus-certainty trade: strong month-to-month deal, but don't prepay a year to an F-rated company. joinsprouthealth.com
No FDA warning letter and a genuinely useful free lab panel, with a competitive $789 twelve-week tirzepatide bundle. But the funnel charges your card before medical intake, a $150 cancellation fee contradicts the "cancel anytime" marketing, pharmacy partners are unnamed, and the public review base is thin for its claimed 35,000 patients. joinelevate.com
A 400,000-patient TRT-first platform (new private-equity backing in 2026) where GLP-1 is one vertical of many. Pricing is fair (~$149/month semaglutide, billed as a $447 quarterly bundle before provider review) and it names its pharmacies — but both named pharmacies carry past FDA or state-board actions, no labs are required for GLP-1, and Trustpilot removed its ~14,000-review profile for guideline violations while the site still displays a 4.9 rating. Better fit for hormone care than weight loss. getpetermd.com
The $149/month flat semaglutide with bundled fitness and nutrition extras is real value on paper. But OrderlyMeds received a June 2026 FDA warning letter, two of its partner pharmacies carry active FDA or state-board actions (one tied to a counterfeit-Ozempic investigation), the BBB flags a pattern of delivery complaints, and tested orders took two to three weeks to arrive. orderlymeds.com
Our previous #1 had a brutal 2026: an FDA warning letter in February, a data breach at its clinical partner affecting up to 1.6 million patients, a class action over affiliate marketing practices, and a 280+ complaint BBB file centered on billing and cancellation. At $299/month semaglutide — just $50 under brand-name Wegovy — the price no longer compensates for the risk. Its large satisfied-customer base (4.3 stars across ~15,000 Trustpilot reviews) keeps it from scoring even lower. medvi.org
The "best" GLP-1 provider depends on what matters most to you. Use this guide to match your priorities to the right provider.
$99/month semaglutide and $129/month tirzepatide, flat at every dose with a lifetime price lock — verified on their live site during this review. Stay month-to-month and confirm the checkout total matches.
The only contender with named compounding pharmacies, certificates of analysis on request, and no FDA warning letter. In 2026, that transparency is the closest thing to peace of mind this category offers.
Zero FDA actions and intake screening that actually checks contraindication history. Also the only fully bilingual (English/Spanish) program in the rankings. Accept the shorter track record, pay monthly.
The only provider requiring a live video consultation before prescribing, with the best portal and support in the category. You pay for it — $299–$399/month — and should read our note on its FDA letter and BBB record first.
Drops and lozenges alongside standard injections — still the only top-3 provider with non-injectable formats, from $199/month.
Compounded GLP-1s are not FDA-approved. Brand-name Zepbound runs $299–$449/month through LillyDirect and Wegovy $349/month through NovoCare (oral pill from $149/month) — no compounding risk, no middleman. If the budget stretches, this is the safest path.
All three analyzers independently scored this field lower than the 2025 cohort. Five of nine providers now carry FDA warning letters, adverse-event reports on compounded GLP-1s passed 1,700, and the FDA has proposed permanently closing the large-scale compounding pathway. The consensus: no provider in this category currently merits a near-perfect score, and the 26-point winner reflects a tougher grading reality, not a weaker winner.
The Value and UX analyzers put Eden at or near the top, but the Quality analyzer ranked it only #4, citing the June 2026 FDA warning letter and the BBB complaint record. The Final Arbiter's math still produced a clear #1 — Eden's price and experience leads were that large — but a buyer who weighs regulatory history above all should look at Shed or Oak instead. That's exactly what the dimension rankings are for.
Oak produced the sharpest internal debate of the cycle. The Quality analyzer rewarded its clean FDA record and genuinely rigorous screening with a #2 ranking; the UX analyzer worried that 54 total Trustpilot reviews is too thin a base to trust at full weight. Remedy Meds finished just two points behind Oak — users who value a long, deep public track record over a clean-but-short one can reasonably flip those two.
Before choosing any GLP-1 provider, consider these category-wide risks that apply to the entire compounded GLP-1 market as of October 2026:
| Feature | 🥇 Eden | 🥈 Shed | 🥉 Oak |
|---|---|---|---|
| Total Score | 26/30 | 24/30 | 22/30 |
| Semaglutide (monthly) | $99 flat, all doses | $199 ($159 w/ 12-mo plan) | $235 flat, all doses |
| Tirzepatide (monthly) | $129 flat, all doses | $299 ($239 w/ 12-mo plan) | $285 flat, all doses |
| FDA Warning Letter | Yes (Jun 2026, marketing claims) | None | None |
| Pharmacies Named | Yes (4 PCAB-accredited 503A) | Yes, + COAs on request | No |
| Medical Oversight | Async, 24–48h approval | Mixed async/video | Async, deepest screening questions |
| Formats | Injections, oral, brand-name | Injections, drops, lozenges | Injections, oral sublingual |
| Contract Terms | Monthly, cancel anytime | 2-month minimum | Monthly available, no refunds post-ship |
| Main Drawback | FDA letter + BBB complaint record | Shipping/billing friction | Short track record, unnamed pharmacies |
Analogy: Choosing a compounded GLP-1 provider in 2026 is like choosing a contractor without a licensing board. Eden quotes the lowest bid from the biggest crew but has a citation on file; Shed shows you every subcontractor's paperwork; Oak has a spotless record but has only built a few houses. There's no inspector coming — so the paperwork each one volunteers IS the inspection.
When a ranked provider cuts prices or a verified deal goes live, we send one email with the math already done. No weekly blasts. Unsubscribe anytime.
Double opt-in — we only add you after you confirm via email. Privacy Policy
MEDVi won our December 2025 verification on quality and consistency. Since then it received an FDA warning letter (February 2026), its clinical partner disclosed a data breach affecting up to 1.6 million patients, a class action was filed over marketing practices, and its BBB complaint file grew past 280 entries. Meanwhile its $299/month price sits just $50 under brand-name Wegovy. Our methodology re-scores every provider from current data on every verification — and the current data moved MEDVi from first to last. No provider holds a ranking here on reputation.
They occupy a narrowing gray zone. The drug shortages that broadly permitted compounding ended by early 2025. Patient-specific compounding through 503A pharmacies continues under an exception that requires a documented clinical need for a different formulation — and the FDA has proposed a rule (pending as of this verification) that would permanently close the large-scale pathway. Practically: the providers on this page are operating today, but the regulatory ground under all of them can shift with limited notice.
Compounded medications are not FDA-approved, and the FDA has logged over 1,700 adverse-event reports involving compounded semaglutide and tirzepatide — many from dosing errors with multi-dose vials. Quality depends entirely on the compounding pharmacy. That's why pharmacy transparency weighs so heavily in our 2026 Quality scores: Shed names its pharmacies and offers testing certificates; several competitors won't tell you who makes their product. Brand-name medications remain the safest option.
If your budget allows it, there's a strong case. LillyDirect sells Zepbound at $299–$449/month depending on dose, and NovoCare sells Wegovy at $349/month, with the oral Wegovy pill from $149/month — all FDA-approved, no compounding risk. The honest math: compounded programs below roughly $150/month (like Eden at $99) still offer real savings; compounded programs near $300/month no longer do.
It no longer exists as a GLP-1 provider. The company rebranded as OneTwenty, a beta-stage longevity membership ($499/year) focused on lab panels and health coaching, where GLP-1s are just one optional prescription pathway with unpublished medication pricing. Its old domain now sits parked. Since the product we originally reviewed is gone, we removed it from the rankings rather than score a different business under an old name.
Generally yes, but check the exit terms first — they're where this category hides its teeth. Shed enforces a two-month minimum with 72-hour cancellation notice. Oak doesn't refund once medication ships. Eden's complaint file clusters around refunds on prepaid multi-month plans. Elevate charges a $150 fee if you cancel mid-assessment. The pattern: start every program month-to-month, never prepay a quarter up front, and keep written records of any cancellation request.
If price is your deciding factor, Eden is the clear choice at $99/month with a lifetime lock — just stay month-to-month and read our billing notes. If you want to know exactly who makes your medication and see the paperwork, Shed is the quality pick with named pharmacies and no FDA letter. If a clean regulatory record and serious intake screening matter most — or you want service in Spanish — Oak earns the bronze, short track record and all.
Remember: compounded GLP-1s are not FDA-approved, and the regulatory window for this entire category is narrowing. Brand-name medications through LillyDirect ($299–$449/mo) or NovoCare ($349/mo injection, oral from $149/mo) remain the safest choice — and in 2026, often a surprisingly competitive one.